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Abstract
Cytotoxic T lymphocytes (CTL) protect against viruses including HIV-1. To avoid viral escape
mutants that thwart immunity, we chose 25 CTL epitopes defined in the context of natural
infection with functional and/or structural constraints that maintain sequence conservation. By
combining HLA binding predictions with knowledge concerning HLA allele frequencies, a metric
estimating population protection coverage (PPC) was computed and epitope pools assembled.
Strikingly, only a minority of immunocompetent HIV-1 infected individuals responds to pools with
PPC >95%. In contrast, virus-naive individuals uniformly expand IFNγ producing cells and mount
anti-HIV-1 cytolytic activity. This disparity suggests a vaccine design paradigm shift from infected to
normal subjects.
Background
Although it has been more than 20 years since the discov-
ery that HIV-1 is the cause of acquired immune deficiency
syndrome (AIDS), we are not yet close to realizing a vac-
cine to halt the devastation created by the AIDS pandemic
[1]. HIV-1 clearance by the human host immune system
and development of effective natural immunity have
never been observed in AIDS patients. Consequently, cor-
relates of immune protection are unknown (reviewed in
[2]). Several features of HIV-1 biology have resulted in
unprecedented challenges to vaccine development [3,4].
First, the virus has extraordinary genetic diversity on a glo-
bal population scale as well as at the level of the single
infected person [5,6]. With up to a billion new viral parti-
cles produced per day in an infected individual, HIV-1
genetic variability can be greater within one host than the
worldwide variability of influenza A virus in any year. This
sequence/epitope variability thwarts effective cellular and
humoral immune responses. Second, HIV-1 infection tar-
gets CD4+ helper T cells, thereby blunting mechanisms
that normally amplify adaptive immunity. Third, HIV-1 is
difficult to neutralize because the viral envelope glycopro-
teins are protected by a glycan shield, and exist in several
distinct conformations, rendering conserved epitopes
largely inaccessible to antibody-mediated neutralization
[4].
CD8+ cytotoxic T lymphocytes have been shown to con-
tribute to HIV-1 containment through direct killing of
infected cells and production of soluble anti-viral media-
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tors [7-9]. In one study, AIDS patients with high anti-HIV-
1 specific CD8+ CTL levels in blood generally exhibit bet-
ter clinical status [10]. Furthermore, in vivo containment
of HIV-1 replication appears coincident with the emer-
gence of specific CTL, well before neutralizing antibody
[8]. Conversely, viral mutations resulting in loss of HIV-1
or simian immunodeficiency virus (SIV) recognition by
CTL are linked to increased viral replication in vivo and
diminished immune function [11,12]. Experimental
depletion of CD8+ T cells prior to SIV infection in mon-
keys leads to uncontrolled viral replication, accelerated
disease and death [13]. Collectively, these data suggest
that the induction of CTL responses to an appropriate
selection of viral CTL epitopes prior to HIV-1 exposure
might comprise one important element in HIV-1 vaccine
development. This current study addresses elicitation of
CTL against conserved HIV-1 epitopes using blood from
healthy donors and the implications of our findings on
future preventive HIV-1 vaccine designs.
Methods
Generation of a consensus HIV-1 proteome
A consensus HIV-1 proteome bearing a consensus
sequence of the HIV-1 gene products (GAG, POL, ENV,
VIF, TAT, REV, VPU/VPX, VPR, and NEF) with the variable
residues masked was obtained as indicated below. First,
multiple sequence alignments for the relevant HIV-1 gene
products including representative sequences from all HIV-
1 clades were retrieved from the HIV databases in Los Ala-
mos [14] (Table 1). Then, sequence variability in the
alignments was computed using a variability metric (V)
formally identical to the Shannon entropy equation [15].
Briefly, V per site is given by:
where Pi is the fraction of residues of amino acid type i,
and M is equal to 20, the number of amino acid types. V
ranges from 0 (total conservation, only one amino acid
type is present at that position) to 4.322 (all 20 amino
acids are equally represented in that position). Note that
in order to achieve the maximum value V = 4.3, at least 20
sequences are required. Gap symbols (-) were considered
for deriving the consensus sequence but are not computed
for the variability calculations. Finally, consensus
sequences with the variable positions masked were
obtained as follows. A variability threshold (Vt) was set
1.0, and at each position in the alignment V was com-
pared to the Vt, if V b Vt the most frequent residue is
selected as the consensus, otherwise if V > Vt a "." symbol
is used to mask the sequence at that position (the HIV-1
consensus proteome generated in such a way is shown in
Additional file 1).
Prediction of peptide-HLA I binding and determination of 
the HLA I-binding profile of CTL epitopes
Peptide-MHCI binding predictions were obtained using
position-specific scoring matrices (PSSMs), also known as
weight matrices or profiles, which are obtained from
aligned peptides known to bind to the relevant MHCI
molecules [16]. PSSMs used in this study were all
obtained from 9mer peptides, and thereby predicted pep-
tide binders were all 9mers. Using this approach it is been
shown that  85 % of true peptide-MHCI binders are
found among the top 2% scoring peptides of a given pro-
tein [16]. The potential binding of each selected CTL
epitope to 55 HLA I molecules for which representative
PSSMs are available was evaluated as follows: A) the
epitope sequence is appended to a random protein of
1000 amino acids in length (always the same) with an
amino acid distribution obtained from HIV-1 sequences;
B) peptide-MHCI binding predictions from this random
protein are obtained using the corresponding PSSMs; C)
binding of the CTL epitope to an HLA I molecule is con-
sidered to occur if its sequence is found among the top 2%
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Table 1: HIV-1 protein sequences used in this study
Sequences*
GENE Total A-A1 B C D F1 F2 G H K O 01 02 04 06 10 11 12 CPZ
G A G 2 0 7 1 0 3 7 2 8 57243351 4 8343435
P O L 2 0 4 1 1 3 4 2 6 54343251 4 1 2 343535
E N V 4 0 8 2 4 1 2 8 5 1 1 7 559321 0 3 3 1 6 353635
V I F 4 2 7 2 8 1 9 0 4 0 1 3 555322 4 1 5 1 2 34341 2 5
T A T 2 1 9 1 1 3 9 2 9 76343241 4 1 4 363435
R E V 2 3 1 1 3 3 9 3 8 1 0 6343241 7 1 2 343435
V P U / V P X 3 3 3 1 4 8 7 5 0 1 8 636321 5 2 5 1 4 343435
V P R 3 6 8 9 1 4 2 4 4 7435322 5 1 6 1 2 343435
N E F 4 4 9 1 2 2 8 2 4 4 44375243 1 1 2 3431 1 34
*HIV-1 sequences were obtained from the HIV database for the indicated clade categories.Medical Immunology 2006, 5:1 http://www.medimmunol.com/content/5/1/1
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ranking peptides. Cycling through the above steps results
in a table consisting of a predicted HLA I binding profile
for each CTL epitope.
Computing the cumulative phenotype frequency
Given a set of HLA I alleles (N), their cumulative pheno-
typic frequency (CPF) in a given population can be com-
puted from the gene and haplotype frequencies of the
individual alleles using the equation 2.
where the EPFi term account for the Expected Phenotypic
Frequency of each of the alleles (i), and the ECPFij term
accounts for the Expected Combined Phenotypic Fre-
quency of each two distinct pair of alleles (ij) in the N set.
EPFi is calculated through equation 3:
EPFi = 2xGFi - (GFi)2   Eq. 3
where GFi is the gene frequency of the allele i. On the
other hand, given a pair of alleles (ij), ECPFij is computed
upon considering whether they belong to the same HLA I
gene (HLA-A, -B, -C) or not. If they do belong to the same
gene, we assume a Hardy-Weinberg equilibrium and cal-
culate ECPF ij as follows:
ECPFij = 2xGFi xGFj;   Eq. 4
However, if the two alleles belong to different genes and
their haplotype frequency is available (HFij) we calculate
ECPFij using the following formula:
ECPFij = 2xHFij - (HFij)2   Eq. 5
If no haplotype frequency is available, ECPFij is computed
as if they belonged to the same gene using equation 4. In
this 'study, HLA I allelic and haplotype frequencies used
for the above calculations were those published by Cao et
al [17], which corresponded to 5 major American ethnic
groups (Black, Caucasian, Hispanic, Native American, and
Asian). Note that for computing CPF, we have used a
method similar to that of Dawson et al. [18] which, unlike
the methods of Schipper [19] and Gulukota [20], consid-
ers haplotype frequencies and hence linkage disequilib-
rium. However, in contrast to Dawson et al., we
minimized the number of peptides to be included in the
vaccine rather than the alleles that are required to be the
binding targets for those peptides.
Selection of minimal a set of epitopes providing a 
determined population protection coverage (PPC)
For a set of CTL epitopes, the PPC defines the population
proportion that could potentially mount an immune
response to any of these epitopes. Given the required HLA
I restriction of CTL responses, the PPC for a set of CTL
epitopes matches the proportion of the population that
exhibits at least one of the HLA I alleles targeted for bind-
ing any of those epitopes, and is in turn given by the CPF
of the targeted HLA I alleles. Provided a set of CTL
epitopes (NCTL) and their binding profiles (HLA I alleles
they bind to), an algorithm for the selection of a minimal
subset of epitopes (K) providing a PPC ≥ 95% was imple-
mented as follows:
1. We begin by considering all independent subsets (X) of
epitopes in NCTL of size K (number of epitopes), begining
with 2.
2. For each independent subset of epitopes, their HLA I
binding profiles are pooled into a single non-redundant
array of HLA I alleles, and the CPF is computed for 5
major American ethnicities using the HLA I gene and hap-
lotype frequencies reported by Cao et al [17]. Only
epitope subsets reaching a CPF ≥ 95% for the five ethnici-
ties are saved and returned by the algorithm.
3. If none of the independent epitope subsets X of size K
is found to reach a CPF ≥ 95% the algorithm increases the
subset size by 1 and loops over 1 through 3.
4. The algorithm stops cycling and returns the results
when at least 4 independent subsets of epitopes of size K
reach a CPF ≥ 95%. If only 3 independent sets of size K are
found to reach a CPF ≥ 95%, the program will cycle once
more and find the subsets of size K + 1 that reach a CPF ≥
95%, and then exit.
HIV-1 specific CTL epitopes and assembly of peptide pools
The 25 peptides considered in this study consisting of
HIV-1 specific CTL epitopes were synthesized by Invitro-
gen Co. (Carlsbad, CA). HPLC analysis showed that the
purity of the synthesized crude peptides was 86–92%. All
peptides had expected masses as confirmed by mass spec-
trometry. Crude peptides were used for initial peptide
binding assays and selected crude peptides were purified
to >96% by reverse phase HPLC for further experiments.
Several peptide pools were obtained by combining an
excess number of CTL epitopes providing a PPC ≥ 95%,
with peptide pool #1 containing all selected peptides and
smaller pools #2–#5 as defined in Results. All peptides
pools were prepared in DMSO at 200 μM each.
Generation of HIV-1 specific T cell lines
Langerhans-like APC cells were differentiated from adher-
ent donor monocytes in DMEM medium supplemented
with 20% donor serum, L-glutamine (2 mM), penicillin
(100 U/ml), streptomycin (100 μg/ml), 2-ME (50 μM).
(DMEM complete), GM-CSF (50 ng/ml), IL-4 (50 ng/ml)
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and TGFβ 1 (10 ng/ml)(Peprotech) for one week. Differ-
entiated Langerhans cells were matured with 1 μg/ml Pep-
tidoglycan (Sigma) overnight. Cells were pulsed with
HIV-1 peptide pools (10 μM total) for 3 h and irradiated
(3000 rad). Fresh donor PBMC were prepared by Ficoll-
Paque (Amersham Biosciences) centrifugation. Donor
PBMC were plated at a density of 107cells/ml together
with 5 × 104/ml peptide loaded irradiated donor Langer-
hans cells in 24 well culture plates in complete DMEM
medium with 10 μM HIV-1 peptide pools. Cultures were
fed with 10 u/ml IL-2 (BD biosciences) five days after
stimulation and re-stimulated with peptide loaded irradi-
ated (3000 rads) fresh donor PMBC every week. Replicate
96 well plates were pulsed with 1 μCi per well 3H Thymi-
dine after 4 days of culture, harvested after 18 h, and 3H
Thymidine incorporation was detected using a β Counter
(Perkin Elmer 1450 LSC).
CTL analysis
A0201+ TAP- deficient T2 hybridoma target cells (ATCC)
or A2 supertype transfected 721.221 cell lines were plated
at a density of 106 cells/ml in 24 well plates. Cells were
pulsed with 10 μM A0201-restricted HIV-1 peptide pool
or 10 μM A0201-restricted HTLV-TAX as negative control
peptide for 18 hours at 37°C. Cells were washed twice
with DMEM media (20% fetal calf serum, L-glutamine (2
mM), penicillin (100 U/ml), streptomycin (100 μg/ml),
2-ME (50 μM). (DMEM media). and pulsed with 100 μC
of 51Cr for 90 minutes at 37°C. Target cells were washed
three times with serum free OptiMEM media (Gibco) to
remove excess 51Cr and plated with sorted HIV-1 specific
CD8+ T cells at 30:1, 10:1, 3:1 and 1:1 ratios. After four
hours of incubation 50 μl of culture supernatant were
mixed with liquid scintillation cocktail (Perkin Elmer
Optiphase supermix) and analyzed for 51Cr release using
a Luminescence Counter (Perkin Elmer 1450 LSC). Per-
cent specific chromium release was calculated using the
formula [(Experimental release- spontaneous release)/
(maximum release in 5% Triton-x100- spontaneous
release)]. To analyze CTL responses to naturally processed
HIV-1 epitopes, TAP sufficient T1 hybridoma target cells
T1 (A0201+, B5101+, CD4+) were infected with 0.5 MOI
HIV-IIIB per cell for 3 hours. Cells were washed and plated
at a density of 106/ml in DMEM media. 2–3 days later,
HIV-IIIB infected T1 cells were used in 51Cr release assay
as described above. Intracellular p24 staining by FACS was
used to demonstrate that essentially all target cells were
HIV-IIIB-infected.
IFNγ-ELISPOT assay on HIV-1 infected donor cells
CD8+ T-cell responses to pools of HIV-1 epitopes were
quantified by gamma interferon (IFN-γ) ELISpot assay as
follows. Peripheral blood mononuclear cells (PBMC) iso-
lated from HIV-1 infected patients were plated at 100,000
per well with peptide pools at a final concentration of 10
μM in anti-interferon gamma mAb 1-D1K (Mabtech,
Stockholm, Sweden) coated polyvinylidene 96-well plates
(Millipore.MA) and processed as previously described
[21]. For each individual peptide, the assay was run in
triplicate. Negative and positive controls were obtained by
incubating individual PBMC with medium alone (nega-
tive control) and phytohemagglutinin (PHA) as a positive
control for naive patients. For the assessment of general
immunocompetence of HIV-1 infected patients, a CEF
peptide pool was used as an internal positive control. The
CEF pool consists of optimal T cell epitopes for CMV/EBV
and Influenza viruses provided by the NIH reagent pro-
gram. Only HIV-1 patients whose blood yielded positive
CEF and/or PHA responses were chosen as subjects for the
present study.
The number of specific IFN-γ secreting T cells was deter-
mined with an automated ELISPOT reader (AID, Strass-
berg, Germany), calculated by subtracting the average
negative control value and expressed as the number of
spot-forming cells (SFC) per 106 input cells. Negative con-
trols were approximately 50 SFC per 106 input cells for
HIV-1 infected patients and around 40 for naïve subjects.
A response was considered positive if there were 50 SFC
per 106 input cells and the activity was at least three times
as great as the mean background activity.
IFNγ – production on HIV-1 specific T cell lines generated 
from naive donors
HIV-1 peptide pool-specific T cell lines were generated as
described above. Two weeks after the second stimulation,
25,000 per well HIV-1 specific T cells were plated into
anti-interferon gamma mAB 1-D1K (Mabtech) coated
polyvinylidene 96-well plates (Millipore) with 25,000 per
well irradiated donor PBMCs and stimulated with 10 μM
of each HIV-1 peptide pool. Plates were processed and
spot forming cells were calculated as described above.
HLA-A 0201-binding assay
A0201+ TAP- deficient T2 hybridoma cells (ATCC) were
plated at a density of 106 cells/ml in 24 well plates. Cells
were pulsed with 10 μM A0201 restricted HIV-1B pep-
tides, 10 μM A0201restricted HTLV-TAX (LLFGYPVYV)
positive control peptide and 5 μg/ml β 2 microglobulin
(BD biosciences) for 18 hours at 37°C in serum free AIM5
media (Gibco). A0201 expression was determined by flow
cytometry (FACSAria) using FITC-conjugated BB7.2 mAb
(BDbiosciences). Mean cell fluorescence (MCF) intensi-
ties were normalized to HTLV-TAX positive control pep-
tide using the formula [(MCF.sample- MCF.control)/
(MCF.HTLV-TAT-MCF.control)].
DimerX staining
A2:Ig fusion protein DimerX (BD Biosciences) was passive
loaded with individual A0201 restricted HIV-1B peptidesMedical Immunology 2006, 5:1 http://www.medimmunol.com/content/5/1/1
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or positive control EBV peptide at 640 molar excess in PBS
pH 7.2 overnight. HIV-1B specific CD8+ cells were stained
with peptide loaded A2:Ig fusion protein DimerX reagent
and detected by PE-conjugated A85-1 mAb (anti-mouse
IgG1, BD biosciences). DimerX staining was determined
by flow cytometry (FACSAria, BD Biosciences). The nega-
tive control straining was obtained using the HIV-1 spe-
cific T cell line and a non-relevant HIV-1 peptide loaded
DimerX. The positive control was obtained using donor
PBMC's stimulated with 1uM BMLF-1 EBV peptide for one
week and then stained with EBV peptide loaded Dimer X.
Generation of HLA allele specific transfectants for peptide 
binding and restriction analysis
Cell lines and RNA isolation
HLA-homozygous human B-lymphoblastoid cell lines (B-
LCL) from the International Histocompatibility Working
Group (IHWG) were thawed and grown in RPMI com-
plete medium (RPMI supplemented with 10% FCS, 2 mM
L-glutamine, 1 mM sodium pyruvate, and 1% pen-strep).
The HLA class I deficient 721.221 LCL line and the
Amphopack 293, retroviral producer line, were main-
tained in DMEM complete medium (DMEM supple-
mented with 10% FCS, 2 mM L-glutamine, 1% pen-strep,
1 mM sodium pyruvate). Total RNA was isolated from 5 ×
106 B-LCL using the RNeasy kit (Qiagen) according to the
manufacturer's instructions. The purified RNA was eluted
in 50 ul RNase-free water and 10 μl of this was used to
synthesize cDNA using an oligo dT primer, dNTP mix,
DTT, and M-MLV reverse transcriptase (200 u) (Gibco
BRL).
Primer, PCR amplification and cloning of PCR products
HLA locus-specific primers were synthesized according to
the information from [22]. Sense and antisense primers
were made for each of HLA-A, HLA-B, and HLA-C with a
HindIII site at the 5' end of sense and a NotI site at the 5'
end of the antisense. PCR amplification was done using 2
μl of cDNA, 1× PCR buffer with Mg, 200 uM each dNTP,
0.3 uM of each primer and 0.5 μl Taq polymerase. The
conditions for PCR were one cycle of 95°C for 5 min prior
to addition of polymerase, followed by 30 cycles of 94°C
for 1 min, 58°C for 1 min, 68°C for 1.5 min and finally
one cycle of 68°C for 4 min. PCR products were analyzed
on a 1.2 % agarose gel and gel purified using a gel extrac-
tion kit (Qiagen # 28704). Subsequently, 6 μl of purified
PCR product was ligated into the pCR2.1 vector using the
TA cloning kit (Invitogen, K2000-01) following the man-
ufacturer's directions. Transformation into INVaF' compe-
tent cells was carried out and plated onto LB/ampicillin
(100 μg/ml) plates. After incubation at 37°C overnight,
colonies were selected, grown and miniprep DNA pre-
pared (QIAprep Spin Miniprep Kit (Qiagen 27104).
Clones were checked for inserts by restriction digestion
with EcoR1. Several clones for each were sent for DNA
sequencing using the vector primers M13 Reverse and T7
promoter. Two additional primers designed to anneal in
the middle of all HLA class I genes in the sense and anit-
sense directions were also used [22]. All sequences were
verified by DNA sequencing.
Subcloning of HLA cDNAs into retroviral vector pLNCX2 and 
generation of viral supernatants
Sequence-verified HLA cDNA clones were digested with
HindIII and Not I and the insert was gel purified and sub-
cloned into the retroviral vector, pLNCX2 (BD Bio-
sciences, cat# 6102-1) which had been linearized with
HindIII and NotI. Plasmid DNA preps were done and
sequence was confirmed once again using the forward and
reverse sequencing primers (BD Bioscience #K1060-F) for
the vector, pLNCX2. Retroviral producer cell lines were
established by transfection of the Amphopack 293 cell
line using the HLA/pLNCX2 DNA. Amphopack 293 cells
(4 × 106) were seeded onto a 100 mm tissue culture dish
in 15 ml of DMEM complete medium and incubated over-
night at 37°C. Five minutes prior to transfection, the
medium was replaced with complete medium containing
chloroquine (25 μM). The semi-confluent cells were
transfected using 20 μg of plasmid DNA in combination
with 61 μ l2 M CaCl2 (0.5 ml total volume) and 0.5 ml 2
× HBS, bubbled in. The solution was added dropwise to
the cells and gently swirled. Plates were incubated at 37°C
for 6–8 h, at which time the medium was removed and
replaced with fresh DMEM complete medium. Plates were
incubated further at 37°C for 48 h. At 48 h post-transfec-
tion the viral supernatant was removed from the plates
and spun at 2000 rpm for 10 min, then filtered through a
0.45 um filter. The supernatant was stored at 4°C for
immediate infection or frozen at -80°C for later infection.
Retroviral infection of 721.221 cells, flow cytometric analysis and cell 
sorting
721.221 cells (EBV transfected B cell line which is MHC
class 1 A, B, C negative) were infected with the retroviral
supernatant using Lipofectamine reagent (Invitrogen
#18324-111). For each infection, 1–3 × 106 cells in log
phase were pelleted, resupended in 100 μl of DMEM com-
plete medium, and transferred to one well in a 24 well
plate. 4 μl of lipofectamine reagent, 2 ml of viral stock,
and 0.2 ml of l M Hepes were added. The plate was spun
for 1–2 h at 2000 rpm and subsequently the medium was
discarded, the cells were washed one time with fresh
medium, and finally were resuspended in 2 ml of fresh
medium. The following day, infected cells were put into
neomycin (G418) selection at 800 μg/ml. Selection was
continued for 5–7 days at which point the concentration
was dropped down to 400 μg/ml. Approximately one
week post-infection, the cells were analyzed for cell-sur-
face expression of HLA. An aliquot of cells was stained
using the monoclonal antibody W6/32 at 1:500, incu-Medical Immunology 2006, 5:1 http://www.medimmunol.com/content/5/1/1
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bated at 4°C for 20 min, washed once (using 1 × PBS con-
taining 2% human AB serum and 1% pen-strep) and then
incubated with a second step of Goat-anti-mouse IgG
FITC at 1:200 for 20 min at 4°C. The cells were washed
twice and then analyzed on the FACS machine. Infected
721.221 cells that showed HLA surface expression (vary-
ing from 5% to 60%) were subsequently expanded,
stained and sorted for W6/32 positive cells. Sorted cells
were expanded in DMEM complete containing 400 μg/ml
G418, and aliquots were frozen. The following 721.221
cell lines are available: A0101, A0201, A0202, A0203,
A0204, A0205, A0206, A0207, A0301, A1101, A2301,
A2402, A2403, A2902, A3101, A3301, A6601, A6801,
A6802, B0702, B0801, B1501, B1502, B1510, B2702,
B2703, B2705. B2706, B3501, B3801, B3909, B39011,
B4002, B4402, B4403, B5101, B5301, B5401, B5502,
B5701, C0102, C0304, C0702.
Results and discussion
Strategy for selection of HIV-1 specific CTL cell epitopes 
and generation of peptide pools
In this study, we approached the formulation of CTL tar-
gets from a collection of 199 unique HIV-1 CTL epitopes
retrieved from the Los Alamos HIV database [14]. The
peptides were all 9mers, which is the optimal peptide
length for MHCI binding, and are known to elicit CTL
responses in one or more HIV-1-infected individuals,
indicating that they are naturally processed during the
course of infection. Identification of processed epitopes
eliminates one hurdle in CTL epitope-based vaccine
design. Nonetheless, a successful CTL-based strategy must
confront the sequence variability of HIV-1 strains and pol-
ymorphism of the human MHCI molecules (HLA I). HIV-
1 sequence variation largely contributes to immune eva-
sion. In fact, it has been suggested that at a population
level, HIV-1 variants have evolved to adapt to CTL
responses [23,24]. Certainly, CTL escape variants can arise
from mutations within and/or flanking HIV-1 CTL
epitopes [12].
To select target epitopes less likely to escape from CTL, we
first subjected representative viruses from all HIV-1 clades
(Table 1) to a Shannon Entropy (H) variability analysis
[25], thereby removing or "masking out" any residue with
H >1. See Additional file 1 for the resulting HIV-1 consen-
sus proteome. All residues in the selected CTL epitopes are
therefore quasi-invariant. The most proximal residue
flanking the C-terminus of the CTL epitope is a determi-
nant for cleavage by the proteasome, and mutations in
that residue can abrogate T cell recognition [26]. Accord-
ingly, we also excluded those CTL epitopes with a C-termi-
nal flanking residue with H >1. As a result, only 37 of the
199 HIV-1 CTL peptides were chosen.
HLA I polymorphisms complicate development of a
broadly protective CTL epitope vaccine by limiting popu-
lation coverage. For a given selection of CTL epitopes, the
population protection coverage (PPC) is given by the pro-
portion of cumulative phenotypic frequency (CPF) of the
HLA alleles restricting these epitopes. CPF can be com-
puted from the HLA gene and haplotype frequency in the
population. Using the HLA I gene and haplotype fre-
quency reported by Cao et al. [17] for five major American
ethnicities (Black, Caucasian, Hispanic, Native American,
and Asian), we developed an algorithm that first com-
puted the binding of each epitope to 55 HLA I alleles and
then selected epitope combinations providing a PPC ≥
95% for all ethnic groups considered (details in support-
ing methods). From this analysis, we predicted that as few
as five epitopes from the 37 conserved HIV-1 specific CTL
epitopes should be recognized by = 95% of the popula-
tion, regardless of ethnicity. Furthermore, we identified 5-
epitope combinations using only 25 of the 37 conserved
HIV-1 specific CTL epitopes (Table 2). These 25 CTL
epitopes were distributed as follows: POL (reverse tran-
scriptase, integrase and protease), 14 epitopes; GAG, 5
epitopes; ENV, 3 epitopes; and NEF, 3 epitopes. None of
the epitopes were found in the five remaining protein
open reading frames (ORFs) encoded by the HIV-1
genome (VIF, TAT, REV, VPU/VPX, and VPR). This distri-
bution reflects, in large part, the overall size as well as
degree of conservation of the different HIV-1 ORFs. Fur-
thermore, visual inspection of the relevant 3D structures
reveals that these epitopes encompass residues that are
important either for structural integrity and/or catalytic
activity. For example, epitopes TLVDVGDAY and
VIYQYMDDL from HIV-1 reverse transcriptase (POL)
bear 6 and 4 residues, respectively, involved in substrate
binding and catalysis [27]. The penalty for mutations at
any of these sites vis-a-vis viral fitness presumably pre-
cludes ready development of escape variants.
A minority of HIV-1 patients responds to HIV-1 specific 
CTL peptide pools
That as few as 5 peptides may provide the requisite PPC
largely stems from their ability to bind to many different
HLA I molecules. The peptide SPRTLNAWV itself is antic-
ipated to bind to eight distinct HLA I allelic variants, offer-
ing a PPC ranging from 35% in Asians to 52% in North
American Indians. Such promiscuous MHCI-peptide
binding often resides in previously defined HLA I super-
types (i.e. alleles with similar peptide binding specificity
[28]), e.g., the peptide SPRTLNAWV binds to the B7
supertype and the peptide AVFIHNFKR to the A3 super-
type. Nevertheless, binding promiscuity is not exclusively
confined to HLA I supertypes. For instance, the peptide
EKEGKISKI is predicted to bind to the alleles B2701,
B3801 B39011, B3909, B4402, B5101 and B0801, which
do not conform to any known supertype, and peptideMedical Immunology 2006, 5:1 http://www.medimmunol.com/content/5/1/1
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LVGPTPVNI is predicted to bind to several alleles within
the A2 supertype (A0201 A0202 A0205 A0209) but addi-
tionally to other non-related alleles of the HLA-B locus
(B2701 and B3801).
In order to assess the accuracy of the predicted PPC, five
peptide pools were created, each solubilized in DMSO
and combining CTL epitopes (200 μM each) to provide a
PPC ≥ 95 % (peptides included in the pools are shown in
Table 3). Peptide 1 pool contained all 25 selected peptides
whereas peptide pools #2 (15 peptides), #3 (13 peptides),
#4 (11 peptides), #5 (7 peptides) comprising  55, 13, 11,
5, 2, respectively, of distinct 5-peptide combinations pro-
ducing ≥ 95% PPC. Peptides pools 1–5 were designed so
that peptides in the smaller pools are contained in the
larger pools. CD8+ T cell responses to these pools were
first checked by IFNγ ELISPOT assay using PBMC samples
from a cohort of 47 HIV-1 infected patients. Patients were
largely heterogeneous with regard to their HLA I back-
ground and included those diagnosed during acute or
chronic HIV-1 with or without HAART therapy and some
long-term non-progressors (Table 4). Furthermore, these
Table 2: CTL epitopes conserved among HIV-1 proteomes
EPITOPE C-(1) Source (2) Position (3) HLA I 
Restriction (4)
Predicted HLA I Restriction (5) PPC(6)
SPRTLNAWV K GAG:p24 148–156:16–24 B0702 B0702 B3501 B5101 B5102 B5103 B5301 
B5401 B5502
0.35
AVFIHNFKR K POL:Integrase 894–902:179–187 A0301 A0301 A1101 A3101 A3301 A6601 A6801 0.35
TLFCASDAK A ENV:gp160 51–59 A0301 A0301 A1101 A3101 A3301 A6801 0.32
FPVRPQVPL R NEF 68–76 B3501 A2902 B0702 B3501 B5101 B5102 B5103 
B5301 B5401
0.32
RAMASDFNL P POL:Integrase 735–743:20–28 A0201 A0201 B2709 C0304 0.31
TLNAWVKVI E GAG:p24 151–159:19–27 A0201 A0201 A0202 A0203 A0204 A0206 0.29
VIYQYMDDL Y POL: Reverse 
Transcriptase
334–342:179–187 A0201 A0201 A0205 A0207 A0214 0.28
LVGPTPVNI I POL:Protease 132–140:76–84 A0201 A0201 A0202 A0205 A0209 B1501 B1516 0.27
TVLDVGDAY F POL: Reverse 
Transcriptase
262–270:107–115 B3501 B1501 B3501 B5701 C0304 0.26
PLVKLWYQL E POL: Reverse 
Transcriptase
576–584:421–429 A0201 A0201 A0202 A0203 0.26
TLNFPISPI E POL: Protease 152–160:96–1004 A0201 A0207 0.23
NTPVFAIKK K POL: Reverse 
Transcriptase
212–220:57–65 A0301 A0301 A6601 C0102 0.22
EKEGKISKI G POL: Reverse 
Transcriptase
197–205:42–50 B5101 B2701 B3801 B39011 B3909 B4402 B5101 B8 0.19
LLWKGEGAV V POL: Reverse 
Transcriptase
956–964:241–249 A0201 A0201 A0204 A0205 A0209 0.18
LTFGWCFKL V NEF 137–145 A0201 A0201 0.18
YQYMDDLYV G POL: Reverse 
Transcriptase
336–344:181–189 A0201 A0201 0.18
GPKVKQWPL T POL: Reverse 
Transcriptase
173–181:18–26 B0801 B0702 B0801 B3501 B8 0.17
RAIEAQQHL L ENV:gp41 557–565:46–54 B5101 B1501 
C0304
B1501 B1517 B5101 C0304 0.13
GLNKIVRMY S GAG:p24 269–277:137–145 B1501 A0203 A1 B1501 0.13
YFPDWQNYT P NEF 120–128 A1 B3701 B5701 A1 B3701 B5701 0.07
WYIKIFIMI V ENV:gp41 680–688:680–688 A2402 A0203 A0206 A2402 0.05
YVDRFFKTL R GAG:p24 296–304:164–172 A2601 A0203 A0204 A0207 A2601 B3801 0.05
FVNTPPLVK L POL: Reverse 
Transcriptase
571–579:416–424 A1101 A1101 0.05
KIQNFRVYY R POL:Integrase 934–942:219–227 A3002 A1 A3002 0.03
DRFFKTLRA E GAG:p24 298–306:166–174 B1402 B1402 B2701 B2702 B2703 B2704 B2705 
B2709
0.03
1) Most proximal C-terminal flanking amino acid residue to the epitope
2) HIV-1 ORF
3) Position in mature protein.
4) HLA-1 restriction of the epitope as retrieved from the Los Alamos HIV database
5) Predicted HLA-1 binding profiles of epitopes were obtained using PSSMs [16].
6) Protection Population Coverage (PPC) was computed for 5 ethnic groups (Black, Caucasian, Hispanic, North American Natives and Asian) in the 
USA population. Each PPC value shown in the table is that of the ethnic group with the lowest PPC for that specific HLA I combination.Medical Immunology 2006, 5:1 http://www.medimmunol.com/content/5/1/1
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patients were immunocompetent as judged by their abil-
ity to elicit responses to a pool of CMV, EBV and Influenza
virus peptides and/or PHA [29]. A summary of the patient
antigen-specific CD8 responses is given in Figure 1. Sur-
prisingly, the percentage of patients that exhibit responses
to the tested pools was far lower than expected, and
ranged from 31% to 45%. There were no significant differ-
ences to HIV-1 peptide pools between HIV-1 infected
patient groups (p < 0.0001) (see Figure 1A and 1).
T cell responses obtained from all HIV-1 naive donors 
primed with HIV-1 specific CTL peptide pools
Errors in the prediction of HLA I binding profiles of
epitopes may have contributed to the above discrepancies
between expected and experimental responses. Nonethe-
less, prediction of peptide-MHCI binding per se is quite
accurate, and in general experimental HLA I binding can
be confirmed for at least 75% of HLA I predicted binders
[30]. Thus, while we do not discard the possibility that
errors in predicting epitopes by HLA I binding profiles
might exist, they cannot account for the great divergence
between the expected CTL responses and those observed
experimentally. More likely, functional impairment of
CTL in chronically HIV-1-infected patients may render
CTLs unable to produce IFNγ [31,32]. In addition, the
specificities of CTL responses change during disease pro-
gression [33]. Those targets of CTL responses observed in
individuals during the course of any viral infection are
Antigen-specific responses to conserved HIV-1 peptide pools in HIV-1-infected and naive individuals Figure 1
Antigen-specific responses to conserved HIV-1 peptide pools in HIV-1-infected and naive individuals. Conserved 
HIV-1 peptides were collected in five pools [1–5]. CTL responses of 47 immunocompetent HIV-1 infected patients to each 
peptide pool were analyzed by IFNγ ELISPOT (Panel A). The same HIV-1 peptide pools were used to prime PBMCs from naïve 
individuals and after two stimulations, similarly tested by IFNγ ELISPOT (Panel B).
Table 3: CTL peptides pools used in this study
Pool Peptides 5-PC* Peptide Sequences
#1 25 55 Those shown in Table 1
#2 15 13 FPVRPQVPL, KIQNFRVYY, AVFIHNFKR, GPKVKQWPL, LVGPTPVNI, TLNAWVKVI, GLNKIVRMY, 
TLFCASDAK, VIYQYMDDL, PLVKLWYQL, SPRTLNAWV, YVDRFFKTL, YFPDWQNYT, 
RAIEAQQHL, FVNTPPLVK
#3 13 11 FPVRPQVPL, KIQNFRVYY, AVFIHNFKR, GPKVKQWPL, LVGPTPVNI, TLNAWVKVI, GLNKIVRMY, 
TLFCASDAK, VIYQYMDDL, PLVKLWYQL, SPRTLNAWV, YVDRFFKTL, YFPDWQNYT
#4 11 5 FPVRPQVPL, KIQNFRVYY, AVFIHNFKR, GPKVKQWPL, LVGPTPVNI, TLNAWVKVI, GLNKIVRMY, 
TLFCASDAK, VIYQYMDDL, PLVKLWYQL, SPRTLNAWV
#5 7 2 FPVRPQVPL, KIQNFRVYY, AVFIHNFKR, GPKVKQWPL, LVGPTPVNI, TLNAWVKVI, GLNKIVRMY
*5-PC: distinct 5-peptide combinations in the peptide pool each providing ≥ 95% PPCMedical Immunology 2006, 5:1 http://www.medimmunol.com/content/5/1/1
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determined by subtle immunodominance patterns influ-
enced by many factors including other HLA molecules
and previous pathogenic encounters [34]. To address
these possibilities, we analyzed responses in HIV-1 naive
individuals by priming PBMC of ten donors at high cell
density with HIV-1 peptide-pool pulsed autologous Lang-
erhans-like cells followed by restimulation with peptide
pulsed fresh PBMCs. We tested the resulting HIV-1 pep-
tide pool specific T cell lines by ELISPOT analysis. (Figure
1B) All donors generated IFNγ with a magnitude signifi-
cantly greater (p < 0.0001) than ELISPOT responses gen-
erated by HIV-1-infected subjects.
Characterization of A0201 restricted responses in HIV-1 
naive individuals
To further evaluate specific T cell responses, we selected
the most common HLA subtype, A0201 for detailed anal-
ysis. Eight HIV-1 peptides with A0201 restriction (Table
2) were pulsed individually onto the TAP deficient
A0201+ T2 hybridoma cell line to analyze functional pep-
tide binding. A positive control peptide derived from the
HTLV-TAX protein [(amino acids 11–19. LLFGYPVYV)]
was used to normalize positive peptide binding (value =
1). A predicted A0301 restricted HIV-1 peptide was used
as a negative control (value = 0). Each HIV-1 peptide was
found to bind A0201 as shown by increased A0201 sur-
face expression on peptide-pulsed T2 cells (Figure 2A).
Subsequently, A0201 restricted HIV-1 peptides were com-
bined in a pool and were used to prime an A0201 donor,
resulting in selective proliferation to the HIV-1 peptide
pool compared to control (Figure 2B). These cells pro-
duced IFNγ upon stimulation with HIV-1 peptide-pulsed
antigen-presenting cells (PBMCs) in ELISPOT assays (Fig-
ure 2C). After three rounds of stimulation, 25% of the
cells in culture were CD8+ and 62% were CD4+ (Figure
2D). Given that ~20–30% of MHCI binding peptides are
predicted to bind to MHCII as well, this result is not unex-
pected (data not shown). We also generated two control
cell lines: the first, a tetanus toxoid specific T cell line with
78% CD4+ and no CD8+ T cells elicited by whole protein
stimulation; and the second, an EBV specific T cell line
with 62% CD8+ and 29% CD4+ cells elicited by stimula-
tion with an immunodominant EBV epitope BMLF1
(GLCTLVAML). CD8+ T cells were sorted from the HIV-1
Generation and characterization of HLA-A0201 restricted HIV-1 peptide-specific T cell lines from uninfected individuals Figure 2
Generation and characterization of HLA-A0201 restricted HIV-1 peptide-specific T cell lines from uninfected 
individuals. Binding of HIV-1 peptides to A0201 was tested using the T2 cell line (panel A). These HIV-1 peptide-stimulated T 
cells generated antigen-specific proliferative responses (panel B). ELISPOT responses to HIV-1 peptide-loaded donor PBMCs 
or PHA stimulation (positive control) as well as to non-peptide loaded donor PBMCs (negative control) (Panel C). Flow cyto-
metric analysis of CD4 and CD8 T cells in HIV-1 peptide-specific T cell lines and indicated control T cell lines (Panel D). CD8+ 
T cells were sorted from the HIV-1 specific T cell line after multiple stimulations in vitro and their peptide specificities deter-
mined by individual peptide-loaded DimerX staining (Panel E). In Panel E, the negative control straining was obtained using the 
HIV-1 specific T cell line and a non-relevant peptide loaded DimerX. The EBV positive control was obtained using donor 
PBMC's stimulated with 1uM BMLF-1 EBV peptide for one week and then stained with EBV peptide loaded Dimer X. One to 
nine percent of CD8 T cells were specific for each one of the selected HIV-1B peptides (Panel F).Medical Immunology 2006, 5:1 http://www.medimmunol.com/content/5/1/1
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specific T cell line after several stimulations in vitro (Fig.
2E, first plot) and their peptide specificities determined by
individual peptide-loaded DimerX staining (Figure 2E).
One to nine percent of CD8+ T cells were specific for each
one of the selected HIV-1B peptides (Figure 2F).
Cytotoxic activity of HIV-1 peptide-specific CD8+ T cells 
derived from HIV-1 naive donors
Next, to test for potential cytolytic activity of the HIV-1
peptide-specific T cell lines, T2 hybridoma cells were
pulsed with A0201 restricted HIV-1B peptide pools and
specific lysis was determined by standard 51Cr release
assay. As shown in Figure 3A, the HIV-1 peptide-specific
CD8+ T cells killed A0201 restricted HIV-1 peptide pool-
pulsed T2 cells with ~50% specific lysis at an E:T ratio of
30:1. The same T2 cells loaded with HTLV-TAX peptide as
a negative control were not lysed. To determine whether
HIV-1 peptide-specific A0201 restricted CTL can recognize
and lyse HIV-1 -infected cells, we infected the T1 hybrid-
oma line (A0201+, B5101+, CD4+) with HIV-IIIB virus
and then determined whether HIV-1 peptide specific
A0201 restricted CTL can recognize HIV-IIIB infected T1
cells and kill target cells in a 51Cr release assay. HIV-1 spe-
cific CD8 T cells from two different A0201 donors recog-
nized and killed 20–28% of HIV-1 infected T1 cells 2 and
3 days after infection at an E:T ratio of 30:1 while unin-
fected T1 cells were not lysed (Figures 3B and 3C). We also
noted that although some of these peptides (for example,
TLNAWYKVI) bind to related alleles, CD8+ T cells stimu-
lated from the A0201* donor fail to specifically lyse pep-
tide-pulsed A0202, A0203 or A0204 targets (Figure 4).
Thus, a given CTL response is less degenerate than peptide
binding to MHC.
As shown in Figure 4, A0201 restricted HIV-1-specific CTL
demonstrate alloreactivity and kill A0202, A0203 and
A0204 transfected 721–221 targets in the absence of HIV-
1 peptide loading. Moreover, in the presence of HIV-1
peptides, alloreactivity against A0202, A0203 and A0204
transfected 721–221 targets decrease as shown by dimin-
ished lysis. These results suggest that A0201 restricted
HIV-1 peptides bind to A0202, A0203 and A0204, replac-
ing possible endogenous peptides that mediate much of
the evident alloreactivity. The analysis of the A0204 trans-
fectant is a clear example of this phenomenon.
Allele-restricted fine specificity of CTL directed at HIV-1  peptides Figure 4
Allele-restricted fine specificity of CTL directed at 
HIV-1 peptides. HIV-1 peptide-specific T cells were gener-
ated from an A0201 donor using predicted A0201-restricted 
HIV-1 peptides (Table 1 and Fig. 1). HIV-1 peptide-specific T 
cells killed the A0201 transfected 721–221 cell line in a pep-
tide-specific manner by 51Cr release assay. To test possible 
cross-reactivity of A0201 restricted HIV-1 peptide-specific 
CTL to other A02 alleles, we utilized A0202, A0203 and 
A0204 transfected 721–221 cells as targets. A0201 restricted 
HIV-1 peptide specific CTLs killed HIV-1 peptide loaded 
A0201 transfected 721–221 targets at a 10:1 ratio.  +pp indi-
cates addition of peptide pool, with solid bar = lysis upon 
+pp and gray bar = lysis with no peptide pool addition.
Cytotoxic activity of HIV-1 peptide-specific A0201 restricted  T cells from normal donors Figure 3
Cytotoxic activity of HIV-1 peptide-specific A0201 
restricted T cells from normal donors. CTL were gen-
erated against a pool of eight A0201 restricted HIV-1 pep-
tides using PBMC. HIV-1 specific CTL lysed HIV-1 peptide 
loaded T2 cells (solid symbols) but not the irrelevant peptide 
loaded T2 cells (open symbols) in 51Cr release assay (Panel 
A). HIV-1 specific CTL generated from 2 different naïve 
donors lysed HIV-IIIB- infected T1 cells (solid symbols) but 
not uninfected T1 cells (open symbols) 2 and 3 days after 
acute infection, in a 51Cr release assay (Panels B and C, 
respectively).M
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Table 4: HIV-1 patient information and CTL responses to peptide pools
PATIENT INFORMATION CTL RESPONSES TO PEPTIDE POOLS AS DETERMINED BY INTERFERON-GAMMA 
ELISPOT (SFC*)
PATIENT ID HLA TYPE DISEASE 
STAGE*
HAART* ON 
HAART 
SINCE
INFECTED 
SINCE
VL* PBMC 
DATE*
Pool 1 Pool 1 Pool 2 Pool 2 Pool 3 Pool 3 Pool 4 Pool 4 Pool 5 Pool 5 CEF* NEG NEG NEG POS
1 Unavailable Unavailable Unavailable NA Unavailable Unavailable 6/22/04 1860 1610 530 510 700 620 10 10 10 10 0 0 0 0 PPP
2 Unavailable Unavailable Unavailable NA Unavailable Unavailable 2/17/04 910 960 20 0 40 40 0 0 10 10 0 20 0 0 PPP
3 Unavailable Chronic No NA Unknown >750000 2/19/04 0 0 0 10000000 6 7 5 0 0 0 P P
4 Unavailable Chronic No NA Unknown >750000 2/26/04 00000000007 0 0 0 0 P P P
5 Unavailable Chronic No NA Unknown 12905 3/4/04 110 150 60 80 90 70 50 30 30 40 266 60 40 50 PPP
6 Unavailable Chronic Yes 4/18/01 Unknown 176 2/26/04 180 130 150 200 150 150 210 250 100 120 163 0 0 0 PPP
7 Unavailable Chronic Yes 1/26/03 Unknown 6030 2/19/04 000000000 1 06 0 0 0 0 P P P
8 Unavailable Chronic Yes NA Unknown >750000 2/24/04 0000000000 > 1000 0 0 0 PPP
9 Unavailable Chronic No NA Unknown >500000 2/19/04 0 0 10 0 30 20 170 150 0 0 540 0 0 0 PP
10 Unavailable Chronic No NA Unknown 35100 2/26/04 1440 1010 1010 760 1040 1070 1050 1080 1270 1160 >1000 10 20 40 PPP
11 Unavailable Chronic No NA Unknown 236000 3/2/04 10 10 30 30 20 20 30 30 30 40 20 10 30 10 PPP
12 Unavailable Chronic No NA Unknown 9030 2/19/04 0000000000 1 4 0 0 0 0 P P
13 Unavailable Chronic No NA Unknown 12000 3/4/04 260 210 190 160 180 210 150 210 150 160 >1000 10 20 0 PPP
14 A11/74, B35/
44, C4/5
C h r o n i c N o N AU n k n o w n 7 4 4 / 2 0 / 0 4 0000000000 8 3 3 0 0 0 P P P
15 A30/33, B13/
14, C5/8
Chronic No NA Unknown 122 4/20/04 60 90 20 0 20 10 20 10 20 20 0 0 10 10 PPP
16 A25/32, B18/
40, C2/12
Chronic No NA Unknown 12700 4/20/04 420 410 340 350 220 370 550 490 620 500 0 10 10 0 PPP
17 a2/30, b44/
57, c5/18
Chronic No NA Unknown 49 4/27/04 380 380 420 470 330 410 490 500 360 250 953 0 0 0 PPP
18 A1/74, B57/
81, C7/18
Chronic No NA Unknown 845 6/3/04 0 20 0 20 10 10 10 0 20 20 ND 0 0 10 PP
19 A3/33, B15/
49, C7/14
Chronic No NA Unknown 49 6/16/04 350 350 170 140 230 270 220 240 110 90 ND 0 0 10 PPP
20 A29, B44, 
C16
Chronic No NA Unknown 807 6/16/04 210 180 130 180 200 260 0 20 0 0 ND 10 0 0 PPP
21 A1/24, B13/
57, C6
Acute No NA Unknown 5490 6/22/04 130 120 110 120 270 23000006 0 0 1 0 0 P P P
22 A1/24, B8/
35, C4/7
Acute Yes 7/21/03 2002, May <50 2/17/04 130 100 30 50 70 40 120 100 70 50 347 0 0 0 PPP
23 A24/32, B35/
41, C4/17
Acute Yes 6/1/02 2002, Jun <50 2/19/04 000000 2 6 0 3 0 0 2 0 0 1 4 0 1 4 6 0 0 1 0 P P P
24 A2/31, B40/
44, C3/16
A c u t e Y e s 9 / 2 / 0 3 2 0 0 3 ,  A u g< 4 0 02 / 2 6 / 0 4 0000000000 4 4 0 0 0 0 P P P
25 A11/30, B15/
35, C3/4
Acute Yes 12/30/03 2003, Dec <400 2/26/04 20 30 10 30 20 30 30 40 10 30 396 20 0 20 PPP
26 A11/24, B35/
38, C4/7
Acute Yes 5/19/99 1999, may <50 3/1/04 00000000006 0 0 2 0 0 P P P
27 A1/24, B14/
35, C4/8
Acute Yes 9/8/03 2003, JUL <400 3/1/04 40 50 40 30 30 60 10 50 30 10 100 0 0 20 PPP
28 A1/11, B18/
52, C12
Acute Yes 8/25/99 1999, SEP <50 3/9/04 0000000000 5 2 0 0 0 0 P P PM
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29 A3/68, B14/
44, B8/16
Acute Yes 9/2/03 2003, AUG <50 3/9/04 250 320 50 50 40 20 0 0 20 20 140000 P P P
30 A1/32, B7/
44, C7/16
Acute Yes 2/18/04 2004, FEB 5,440 4/20/04 40 20 100 90 120 110 170 120 180 220 433000 P P P
31 A2/3, B7/44, 
C5/7
Acute Yes 8/1/97 1997-AUG 149 4/20/04 2000000 1 0000 4 4 3 0 1 0 0 P P
32 A33, B53, C4 Acute Yes 12/14/00 2000-NOV <50 4/22/04 0000000000 0000 P P P
33 A1/68, B7/8, 
C7/7
Acute Yes 4/23/04 2004-APR 853 5/6/04 10 1000000 1 000 N D000 P P P
34 A3/24, B40/
57, C3/7
Acute Yes 11/5/03 2003-NOV <50 5/12/04 220 170 190 170 190 120 10 30 0 10 0 30 10 20 PPP
35 A26/68, B44/
71, C3/7
Acute Yes 12/22/98 1996-NOV <50 5/13/04 0 0 0 20 10 10 0 10 10 10 20 10 10 10 PPP
36 A2/26, B53/
57, C4/18
Acute Yes 5/24/01 2001, MAY <400 6/23/04 00000 1 00000 0 0 1 0 0 P P P
37 A2/74, B51/
53, C4/14
Acute Yes 8/22/01 2001, AUG <50 6/22/04 0 10 0 10 20 20 0 20 0 10 986000 P P P
38 A1/2, B8/15, 
C3/7
Acute Yes 3/9/99 1999, MAR 1,111 5/19/04 420 430 480 420 500 410 430 410 430 480 326000 P P P
39 A1/2, B7/8, 
C7/7
Acute No 7/22/02 2002, JUL <400 3/2/04 10 20 10 10 0 10 10 0 0 10 >1000 0 0 10 PPP
40 A23/24, B44/
60, C3/14
Acute No NA 2004, FEB 1,580 3/15/04 210 220 90 90 80 10000007 0 0 2 0 0 P P P
41 A1/3, B8/15, 
C7
Acute No NA 2003, AUG 56,100 4/14/04 260 210 380 480 360 290 300 430 430 440 ND000 P P P
42 A2/31, B15/
51, C3/15
Acute No NA 2003-MAY 2,620 6/3/04 410 430 480 410 490 430 440 410 400 470 116 0 0 20 PPP
43 A3/24, B14/
35, C8/12
Acute No NA 2000-MAY 883 5/26/04 250 250 40 30 20 40 40 40 40 30 80 0 0 10 PPP
44 A1/3, B35/
40, C4/15
Acute No NA 2003-OCT 121,000 5/13/04 910 1150 1010 1010 1100 1080 980 1330 930 1090 260000 P P P
45 A3/41, B14/
35, C8/12
Acute No NA 2002, FEB 29,000 6/22/04 950 1090 30 40 40 60 40 40 50 60 143000 P P P
46 A2/32, B15/
39, C4/15
Acute No NA 2001, OCT 48,000 6/23/04 1200 1200 1150 1460 1660 1300 1460 1290 1390 1540 160 0 10 10 PPP
47 A3/68, B35/
44, C4/7
Acute No NA 1999, AUG 667 5/26/04 10 30 0 30 10 20 0 20 10 0 ND 0 20 10 PPP
CTL responses were determined by the interferon-gamma elispot assay
SFC*: Spot Forming Colonies 
DISEASE STAGE*: refers to the stage at the time of diagnosis 
HAART*: Patients were receiving HAART treatment at the time of PBMC collection
VL*: Viral Load at the time of PBMC sampling in copies/ml
PBMC DATE*: Date PBMC samples were collected
CEF: Response to CMV, EBV and Influenza A peptide pools. 
POS is a PHA response where PP = high and PPP = highest responses related to non-stimulated controls. Both PP and PPP are equivalent to responses form normal individuals. 
NA, Not Applicable
Table 4: HIV-1 patient information and CTL responses to peptide pools (Continued)Medical Immunology 2006, 5:1 http://www.medimmunol.com/content/5/1/1
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Conclusion
The present report supports the notion that T cell
responses in HIV patients are impaired and argues for
optimizing the composition of epitope-based vaccines
using data obtained from naive individuals. However, the
responses present in HIV-1-infected subjects and the abil-
ity to grow peptide-specific CD8 T cells from naive indi-
viduals are not directly comparable. Further experimental
work shall include analysis of the T cell responses in naive
and HIV-1-infected patients using in vitro stimulated CD8
T cells and HIV-specific CTL epitopes. Perhaps this
approach will elucidate whether clonal deletion or anergy
exists, for example.
Overall, these findings demonstrate that normal, HIV-1
naive individuals possess T cells capable of recognizing
and expanding against conserved segments of the HIV-1
proteome. Although only a minority of chronically HIV-1-
infected patients responds to pools of such epitopes, viral
protective responses can be elicited from all normal sub-
jects examined. Thus, the absent response in HIV-1-
infected patients is not a consequence of intrinsic holes
within the human T cell repertoire, but rather the sequelae
of chronic exposure to antigens, immunodominance pat-
terns and/or cellular dysfunction. In this regard, the abil-
ity of HIV-1 to drive cellular responses away from
relevant, invariant segments capable of affording protec-
tion toward mutable epitopes that escape CTL-based
destruction is reminiscent of the anti-HIV-1 antibody
response in chronically infected patients [4]. In the latter,
antibodies are directed to the variable loops of the HIV-1-
gp160 envelope protein rather than invariant potential
neutralization sites. Thus, viral escape mechanisms send
both T cells and B cells off in unproductive directions.
That human T cell responses can be elicited from virus-
naive individuals to conserved segments of the HIV-1 pro-
teome argues that CTL-directed vaccines may target these
epitopes, and underscores the importance of assessing
immune responses of normal individuals as well as HIV-
1-infected patients. Beyond HIV-1, immunoprotection
against other chronic infectious diseases such as malaria
as well as neoplastic disorders may benefit from a para-
digm shift in vaccine design, focusing on potential
immune responses in normal rather than in patient pop-
ulations.
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